AGA SectionAmerican Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Abbreviations used in this paper
Cited by (0)
This article has an accompanying continuing medical education activity on page e16. Learning Objective: Upon completion of the CME activity, successful learners will be able to describe the relative risk for the occurrence of HBV reactivation according to the type immunosuppressive drug therapy used and the serologic profile of the HBV infected individual. The learner will also be able to describe how HBV screening is essential to appropriate use of antiviral prophylaxis as a means of reducing the risk of HBV reactivation.
Reprint requests Address requests for reprints to: Chair, Clinical Practice and Quality Management Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: [email protected]; telephone: (301) 941-2618.
Conflicts of interest The authors disclose the following: R.P.P. has served as a consultant for Gilead Sciences and Novartis. R.G. has served as a consultant for Gilead Sciences, Novartis, AbbVie, Merck, and Idenix. Y.T.F.-Y. discloses no conflicts.